Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Eve ...

TransMedics (TMDX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this medical technology company have returned +50.5% over the past month versus the Zacks S&P 500 composite's -1.6% change. The Zacks Medical - Instruments industry, to which TransMedics belongs, has lost 2.5% over this period. Now the key question is: Where could the stock be headed in the near term?Wh ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. (Exact name of registrant as specified in its charter) Massachusetts 83-2181531 (State or other jur ...

TransMedics Group, Inc. (NASDAQ:TMDX) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President & Chief Executive Officer Stephen Gordon - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Josh Jennings - TD Cowen Suraj Kalia - Oppenheimer & Company Operator Good afternoon and welcome to the TransMedics First Quarter 2024 Earnings Conference Call. At this time, all participants are ...

TransMedics (TMDX) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 800%. A quarter ago, it was expected that this medical technology company would post a loss of $0.08 per share when it actually produced earnings of $0.12, delivering a surprise of 250%.Over the last four quarter ...

Exhibit 99.1 TransMedics Reports First Quarter 2024 Financial Results Andover, Mass. – April 30, 2024 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2024. Recent Highlights ▪ Net revenue of $96.9 million in the first quarter of 2024, a 133% increase compared to the first quarter of 2023 ▪ Generated n ...

Wall Street analysts expect TransMedics (TMDX) to post quarterly loss of $0.05 per share in its upcoming report, which indicates a year-over-year increase of 37.5%. Revenues are expected to be $83.32 million, up 100.5% from the year-ago quarter.The current level reflects an upward revision of 32.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a compa ...

The most recent trading session ended with TransMedics (TMDX) standing at $88.88, reflecting a -1.9% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.11%, and the technology-dominated Nasdaq saw an increase of 0.1%.Prior to today's trading, shares of the medical technology company had gained 21.63% over the past month. This has outpaced the Medical sector's loss of 4.52% and the S&P 500's loss of ...

TransMedics (TMDX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 30. O ...

TransMedics (TMDX) closed the most recent trading day at $84.74, moving +0.69% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.87% for the day. Elsewhere, the Dow saw an upswing of 0.67%, while the tech-heavy Nasdaq appreciated by 1.11%.Shares of the medical technology company witnessed a gain of 18.77% over the previous month, beating the performance of the Medical sector with its loss of 6.67% and the S&P 500's loss of 3.97%.Investors will be eagerly wa ...